Zydus Lifesciences Ltd Share Price – NSE /  BSE

Pharmaceuticals, Mid Cap

Zydus Lifesciences has received a Warning Letter from the United States Food and Drug Administration (USFDA) relating to its formula on manufacturing facility located at Baddi, Himachal Pradesh.

The Warning Letter was issued in response to a request for records pursuant to sec on 704(a)(4) of the Federal Food, Drug, and Cosmetic Act, and does not pertain to any onsite inspection of the facility by the USFDA. The communication references technical observations regarding the use of purified talc that did not meet the current United States Pharmacopeia (USP) requirements.

The company added that the said Warning Letter will not impact current operations and supplies from the Baddi site.

The Baddi manufacturing facility was last subjected to an on-site inspection by the USFDA in August 2025. Subsequent to the conclusion of the inspec on, the Company received the Establishment Inspection Report (EIR) in October 2025, with the final compliance status classified as Voluntary Ac on Indicated (VAI).

The warning letter was issued in response to a request for records pursuant to a section of the Federal Food, Drug, and Cosmetic Act, and does not pertain to any on-site inspection of the facility by the US FDA.

The communication references technical observations regarding the use of purified talc that did not meet the current United States Pharmacopeia (USP) requirements.

We believe that the said warning letter will not impact current operations and supplies from the Baddi site,? Zydus Lifesciences said in a statement.

The Baddi manufacturing facility was last subjected to an on-site inspection by the USFDA in August 2025.

Subsequent to the conclusion of the inspection, the company received the establishment inspection report (EIR) in October 2025, with the final compliance status classified as voluntary action indicated (VAI).

Zydus Lifesciences is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company?s consolidated net profit jumped 8.68% to Rs 1,272.5 crore on 16.22% increase in revenue from operations to Rs 7,587 crore in Q4 FY26 over Q4 FY25.

Powered by Capital Market - Live News

Zydus Lifesciences Ltd rose for a fifth straight session today. The stock is quoting at Rs 1105.45, up 1.81% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.24% on the day, quoting at 23849.9. The Sensex is at 75777.13, down 0.12%. Zydus Lifesciences Ltd has added around 23.94% in last one month.

Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has added around 6.44% in last one month and is currently quoting at 24716, up 0.2% on the day. The volume in the stock stood at 14.03 lakh shares today, compared to the daily average of 23 lakh shares in last one month.

The benchmark June futures contract for the stock is quoting at Rs 1114.05, up 2.08% on the day. Zydus Lifesciences Ltd is up 18.87% in last one year as compared to a 3.64% fall in NIFTY and a 15.5% fall in the Nifty Pharma index.

The PE of the stock is 29.59 based on TTM earnings ending March 26.

Powered by Capital Market - Live News

Zydus Lifesciences and its various subsidiaries has invested balance 9.01 crore for subscription of 90,17,848 equity shares under Tranche 2, 3 and 4 of Torrent Urja 25, representing 22.06% of its paid-up share capital.

Pursuant to the same, the transaction of subscription of shares of Torrent Urja 25 is consummated on 19 May 2026.

In June 2025 under Tranche 1, the company and its subsidiaries had invested Rs 3.86 crore for subscription of 38,64,792 equity shares of Torrent Urja 25, representing 22.06% of its paid-up share capital.